Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 30 peer-reviewed journal articles Updated
Neurology · Myotonic Dystrophy Type 1

Staying Ahead: Your Long-Term Health Plan

At a Glance

Proactive, lifelong monitoring is essential for people with Myotonic Dystrophy Type 1 (DM1) to detect silent complications early. A comprehensive health plan includes annual heart monitors, regular lung function tests, and routine screenings for cataracts and endocrine issues.

Because Myotonic Dystrophy Type 1 (DM1) can affect systems that don’t always show obvious symptoms—like the heart and lungs—proactive, lifelong monitoring is your most powerful tool for maintaining your health [1][2]. The goal of surveillance is to detect “silent” changes early, when they are most manageable, and to prevent the leading causes of complications in DM1: heart rhythm issues and respiratory weakness [3][4].

Your Surveillance Schedule

Expert consensus recommendations, such as those from the Myotonic Dystrophy Foundation (MDF), provide a roadmap for what high-quality monitoring looks like [5].

System Test Frequency Why it matters
Heart ECG & 24-hour Holter Annual [6] Detects “silent” rhythm or conduction delays [7].
Heart Echocardiogram At diagnosis; periodic [1] Monitors heart pump strength and structure [8].
Lungs PFT (FVC, MIP/MEP) Every 6–12 months [9] Tracks breathing muscle strength [10][11].
Sleep Sleep Study (Polygraphy) At diagnosis; as needed [12] Screens for sleep apnea or nocturnal hypoventilation [13].
Eyes Slit-lamp exam Every 1–2 years [5] Checks for early-onset cataracts [14][15].
Endocrine HbA1c / Fasting Glucose Annual [5] Screens for insulin resistance or diabetes [16][17].
Endocrine Thyroid (TSH/T4) Annual [5] Monitors for thyroid dysfunction [18][19].

Managing “Silent” Risks

The two most critical areas for long-term safety are the heart and the respiratory system [3][4].

  • Heart Health: Up to 75% of adults with DM1 develop conduction defects [20]. Because a routine ECG only captures a few seconds of your heart’s rhythm, a 24-hour Holter monitor is essential for catching issues that come and go [7][21].
  • Breathing Support: Respiratory failure is the most common cause of death in DM1 [4][3]. Tracking your Forced Vital Capacity (FVC) allows your team to intervene with Non-Invasive Ventilation (NIV/BiPAP) before you experience a crisis [9][22].

Empowered Survivorship

Living with a chronic condition requires mental and emotional resilience. It is common to experience “scan anxiety” or feel overwhelmed by frequent appointments [23].

  • Connect with a Community: Consider connecting with organizations like the Myotonic Dystrophy Foundation (MDF). Joining a patient registry or support group can help you find a community, stay informed about clinical trials, and feel less isolated [5].
  • Self-Advocacy: Always carry your Medical Emergency Card [24]. In any medical setting, remind your providers about the specific risks of anesthesia and the importance of monitoring your heart and breathing [25][5].
  • Symptom Tracking: Keep a simple log of how you feel. Note any new heart flutters, morning headaches (a sign of poor sleep breathing), or changes in your energy levels [13][26].
  • Mental Health: Don’t ignore the psychological impact of DM1. Cognitive Behavioral Therapy (CBT) has been shown to help patients manage fatigue and stay socially engaged [27][28].

Remember, you are the most important member of your care team. Proactive monitoring isn’t just about “checking for problems”—it’s about empowering yourself to live as fully and safely as possible [29][30].

Common questions in this guide

Why do I need a 24-hour Holter monitor if my regular ECG is normal?
A routine ECG only records your heart rhythm for a few seconds. Because adults with DM1 often develop heart rhythm issues that come and go, a 24-hour Holter monitor is needed to catch these silent problems before they become dangerous.
How often should my lung function be tested if I have DM1?
Experts recommend having pulmonary function tests every 6 to 12 months. Tracking your breathing muscle strength allows your doctor to prescribe non-invasive ventilation, like BiPAP, before you experience a respiratory crisis.
What are the warning signs of breathing problems during sleep?
Waking up with morning headaches, daytime fatigue, or finding it difficult to take a deep breath when lying down are key warning signs. These symptoms suggest poor sleep breathing and may mean you need a sleep study.
What other routine tests do I need besides heart and lung monitoring?
In addition to your heart and lungs, you should have your eyes checked every one to two years for early-onset cataracts. Annual blood tests are also needed to monitor your thyroid function and screen for insulin resistance or diabetes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specialized center or multidisciplinary team will oversee my long-term monitoring?
  2. 2.If my ECG is normal, why do I still need an annual 24-hour Holter monitor and echocardiogram?
  3. 3.At what specific decline in my lung function (FVC) will we need to discuss starting nocturnal ventilation (BiPAP)?
  4. 4.How will we monitor my thyroid and blood sugar levels, and how often?
  5. 5.Are there local resources or therapists you recommend for managing the stress of chronic illness monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Do I Need a Pacemaker or ICD for Myotonic Dystrophy?

References

References (30)
  1. 1

    Echocardiographic Features of Cardiac Involvement in Myotonic Dystrophy 1: Prevalence and Prognostic Value.

    Russo V, Capolongo A, Bottino R, et al.

    Journal of clinical medicine 2023; (12(5)) doi:10.3390/jcm12051947.

    PMID: 36902735
  2. 2

    Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease.

    Gutiérrez Gutiérrez G, Díaz-Manera J, Almendrote M, et al.

    Neurologia 2020; (35(3)):185-206 doi:10.1016/j.nrl.2019.01.001.

    PMID: 31003788
  3. 3

    Sudden Death Caused by Bilateral Diaphragmatic Eventration in Myotonic Dystrophy Type 1.

    Wu S, Prahlow JA

    The American journal of forensic medicine and pathology 2025; (46(4)):330-336 doi:10.1097/PAF.0000000000001073.

    PMID: 40928346
  4. 4

    Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy.

    Gallinoro E, Papa AA, Rago A, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2018; (37(3)):227-231.

    PMID: 30838353
  5. 5

    Consensus-based care recommendations for adults with myotonic dystrophy type 1.

    Ashizawa T, Gagnon C, Groh WJ, et al.

    Neurology. Clinical practice 2018; (8(6)):507-520 doi:10.1212/CPJ.0000000000000531.

    PMID: 30588381
  6. 6

    [Myotonic dystrophy type 1 - a rare cause of bradycardia in the young].

    Kataja Knight A, Tidehag L, Mattsson G, Magnusson P

    Lakartidningen 2020; (117()).

    PMID: 31961442
  7. 7

    An evaluation of 24 h Holter monitoring in patients with myotonic dystrophy type 1.

    Joosten IBT, Janssen CEW, Horlings CGC, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2023; (25(1)):156-163 doi:10.1093/europace/euac104.

    PMID: 35851806
  8. 8

    Diastolic heart dysfunction is correlated with CTG repeat length in myotonic dystrophy type 1.

    Park JS, Kim N, Park D

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2018; (39(11)):1935-1943 doi:10.1007/s10072-018-3530-z.

    PMID: 30094526
  9. 9

    Predictors of respiratory decline in myotonic dystrophy type 1 (DM1): a longitudinal cohort study.

    Mazzoli M, Ariatti A, Garuti G, et al.

    Acta neurologica Belgica 2021; (121(1)):133-142 doi:10.1007/s13760-020-01425-z.

    PMID: 32651874
  10. 10

    Factors Influencing the Severity and Progression of Respiratory Muscle Dysfunction in Myotonic Dystrophy Type 1.

    Hartog L, Zhao J, Reynolds J, et al.

    Frontiers in neurology 2021; (12()):658532 doi:10.3389/fneur.2021.658532.

    PMID: 33927684
  11. 11

    Utility of maximum inspiratory and expiratory pressures as a screening method for respiratory insufficiency in slowly progressive neuromuscular disorders.

    Wenninger S, Stahl K, Wirner C, et al.

    Neuromuscular disorders : NMD 2020; (30(8)):640-648 doi:10.1016/j.nmd.2020.06.009.

    PMID: 32690350
  12. 12

    Evaluation of Sleep-Disordered Breathing and Respiratory Dysfunction in Children with Myotonic Dystrophy Type 1-A Retrospective Cross-Sectional Study.

    Basa M, Pesovic J, Savic-Pavicevic D, et al.

    Biomedicines 2025; (13(4)) doi:10.3390/biomedicines13040966.

    PMID: 40299556
  13. 13

    Sleep-disordered breathing and effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with myotonic dystrophy type I.

    Spiesshoefer J, Runte M, Heidbreder A, et al.

    Neuromuscular disorders : NMD 2019; (29(4)):302-309 doi:10.1016/j.nmd.2019.02.006.

    PMID: 30898523
  14. 14

    Gender effect on onset, prevalence and surgical treatment of cataract in patients with Myotonic Dystrophy type 1.

    Scutifero M, Lanza M, Petillo R, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2022; (41(3)):105-110 doi:10.36185/2532-1900-N75.

    PMID: 36349183
  15. 15

    Myotonic Muscular Dystrophies.

    Johnson NE

    Continuum (Minneapolis, Minn.) 2019; (25(6)):1682-1695 doi:10.1212/CON.0000000000000793.

    PMID: 31794466
  16. 16

    Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus.

    Luo L, Zhu C, Yang S, et al.

    Frontiers in neurology 2025; (16()):1640563 doi:10.3389/fneur.2025.1640563.

    PMID: 41018201
  17. 17

    Asymptomatic myocardial infarction in a patient with myotonic dystrophy type 1.

    Seki Y, Yamada T, Kiyosue A, et al.

    Journal of cardiology cases 2022; (26(4)):248-251 doi:10.1016/j.jccase.2022.05.004.

    PMID: 36187313
  18. 18

    Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study.

    Spaziani M, Semeraro A, Bucci E, et al.

    Journal of endocrinological investigation 2020; (43(5)):663-675 doi:10.1007/s40618-019-01156-w.

    PMID: 31786795
  19. 19

    Managing thyroid cancer in Steinert's disease: the role of radiofrequency ablation.

    Solis-Pazmino P, Carvajal MA, García M, et al.

    Journal of surgical case reports 2023; (2023(6)):rjad381 doi:10.1093/jscr/rjad381.

    PMID: 37397070
  20. 20

    Cardiac Pathology in Myotonic Dystrophy Type 1.

    Mahadevan MS, Yadava RS, Mandal M

    International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111874.

    PMID: 34769305
  21. 21

    Twenty-four-hour ambulatory ECG monitoring relevancy in myotonic dystrophy type 1 follow-up: Prognostic value and heart rate variability evolution.

    Gamet A, Degand B, Le Gal F, et al.

    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2019; (24(1)):e12587 doi:10.1111/anec.12587.

    PMID: 30101452
  22. 22

    New Insights in Adherence and Survival in Myotonic Dystrophy Patients Using Home Mechanical Ventilation.

    Seijger C, Raaphorst J, Vonk J, et al.

    Respiration; international review of thoracic diseases 2021; (100(2)):154-163 doi:10.1159/000511962.

    PMID: 33461194
  23. 23

    Diabetes distress and diabetes burnout explored in various areas of life in patients with type 1 diabetes: effect of short-term psychological intervention.

    Cyranka K, Klupa T, Pilecki M, et al.

    Endocrine 2024; (85(2)):676-684 doi:10.1007/s12020-024-03760-0.

    PMID: 38448676
  24. 24

    [Medical emergency card for Steinert's disease: an unmet need].

    Rosado-Bartolomé A, Domínguez-González C

    Revista de neurologia 2023; (76(1)):15-19 doi:10.33588/rn.7601.2022380.

    PMID: 36544372
  25. 25

    Laparoscopic cholecystectomy under total intravenous anaesthesia in a patient with myotonic dystrophy type 1 (Steinert's disease) - a case report.

    Karras G, Nikouli E, Kiamiloglou B

    Folia medica 2022; (64(2)):333-336 doi:10.3897/folmed.64.e59905.

    PMID: 35851789
  26. 26

    Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1.

    Sansone VA, Proserpio P, Mauro L, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021; (17(12)):2383-2391 doi:10.5664/jcsm.9438.

    PMID: 34170223
  27. 27

    Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.

    Okkersen K, Jimenez-Moreno C, Wenninger S, et al.

    The Lancet. Neurology 2018; (17(8)):671-680 doi:10.1016/S1474-4422(18)30203-5.

    PMID: 29934199
  28. 28

    Cognitive Deficits, Apathy, and Hypersomnolence Represent the Core Brain Symptoms of Adult-Onset Myotonic Dystrophy Type 1.

    Miller JN, Kruger A, Moser DJ, et al.

    Frontiers in neurology 2021; (12()):700796 doi:10.3389/fneur.2021.700796.

    PMID: 34276551
  29. 29

    Myotonic dystrophy type 2: the 2020 update.

    Meola G

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(4)):222-234 doi:10.36185/2532-1900-026.

    PMID: 33458578
  30. 30

    Clinical and genetic characteristics of childhood-onset myotonic dystrophy.

    Stokes M, Varughese N, Iannaccone S, Castro D

    Muscle & nerve 2019; (60(6)):732-738 doi:10.1002/mus.26716.

    PMID: 31520483

This page provides long-term monitoring guidelines for Steinert myotonic dystrophy (DM1) for educational purposes. Always consult your multidisciplinary healthcare team to tailor a surveillance plan to your specific needs.

Get notified when new evidence is published on Steinert myotonic dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.